Merck & Co Inc (LTS:0QAH)
$ 131.3 0 (0%) Market Cap: 249.37 Bil Enterprise Value: 272.91 Bil PE Ratio: 20.67 PB Ratio: 5.61 GF Score: 81/100

Merck & Co Inc at Barclays Global Healthcare Conference Transcript

Mar 15, 2023 / 06:35PM GMT
Release Date Price: $106.42 (+0.08%)
Carter Lewis Gould
Barclays Bank PLC, Research Division - Senior Analyst

Okay. Good afternoon, and welcome to Day 2 of the Barclays Global Healthcare Conference. My name is Carter Gould, senior biopharma analyst here at Barclays, and I'm pleased to welcome Merck to the stage.

Merck has been one of our top-ranked names for a bit here and certainly came -- coming off a pretty stellar 2022, followed that up with a solid start to 2023 with PAH data, which we're going to touch on.

Joining us from the company, President of Merck Human Health, Jannie Oosthuizen, as well as Peter Dannenbaum from the IR team. Peter, Jannie, thank you very much for joining us today.

Jannie Oosthuizen
Merck & Co., Inc. - Senior VP & President Merck U.S. Human Health

Well, thank you for having us.

Carter Lewis Gould;Jannie Oosthuizen
Barclays Bank PLC, Research Division - Senior Analyst;Merck & Co., Inc.

So we can hop into Q&A unless you wanted to make any opening comments.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot